Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436312 | 0.84 | AMY1A (0.37) | LMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL168783 | 0.81 | CA2 (0.48) | MAPK1ALDH1A1CYP1A2 | |
| SCHEMBL30360640 | 0.81 | CA2 (0.48) | MAPK1ALDH1A1CYP1A2 | |
| SCHEMBL8863967 | 0.80 | RAB9A (0.46) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL31128553 | 0.80 | AR (0.51) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL3349899 | 0.80 | RAB9A (0.50) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL313099 | 0.80 | AR (0.51) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL14104821 | 0.80 | GRM5 (0.46) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL16957547 | 0.80 | RAB9A (0.46) | RAB9ALMNAMAPK1HTTTUBB1 | |
| SCHEMBL19808999 | 0.78 | LMNA (0.49) | RAB9ALMNAMAPK1HTTTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0607077-A1 | Salts of 4-pyrimidinone derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1994-07-20 | — | — | EP | claimed |
| EP-0500409-A1 | 4-Pyrimidinone derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1992-08-26 | — | — | EP | claimed |
| CN-114249680-B | Indole derivatives, and synthesis method and application thereof | 深圳市乐土生物医药有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-114249680-A | Indole derivatives, and synthesis method and application thereof | 深圳市乐土生物医药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| CN-102307860-B | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2014-07-02 | — | — | CN | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-7022733-B2 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| CN-1606551-A | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH CORP (US) | 2005-04-13 | — | — | CN | disclosed |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2005-02-17 | — | — | US | disclosed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6774248-B2 | ANTICANCER AGENTS; ANTICHOLESTEROL AGENTS; COGNITION ACTIVATORS; RHEUMATIC DISEASES | WYETH | 2004-08-10 | — | — | US | disclosed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | disclosed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
| EP-0607077-A1 | Salts of 4-pyrimidinone derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1994-07-20 | — | — | EP | disclosed |
| EP-0500409-A1 | 4-Pyrimidinone derivatives, their preparation and their application in therapy | SYNTHELABO (FR) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, ESRRA | RAB9A 2271/4885LMNA 2929/4885MAPK1 1425/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | RAB9A 2212/4885LMNA 4018/4885MAPK1 2909/4885 |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | RAB9A 2462/4885LMNA 2854/4885MAPK1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.